{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:23:37Z","timestamp":1788351817173,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,2]]},"DOI":"10.7759\/cureus.115641","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:09:02Z","timestamp":1788350942000},"source":"Crossref","is-referenced-by-count":0,"title":["Suprabasal Blistering as a Diagnostic Pitfall in Bullous Pemphigoid: Histopathologic-Immunofluorescence Discordance Complicated by Sepsis"],"prefix":"10.7759","author":[{"given":"Adriana V","family":"Saenz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol","family":"Cazares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarahi G","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro A","family":"Cardenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"de La O","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K","family":"Bustillos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20743","article-title":"The global incidence of bullous pemphigoid: a systematic review and meta-analysis","volume":"186","author":"Persson MS","year":"2022","unstructured":"Persson MS, Begum N, Grainge MJ, Harman KE, Grindlay D, Gran S. The global incidence of bullous pemphigoid: a systematic review and meta-analysis. Br J Dermatol. 2022, 186:414-25. 10.1111\/bjd.20743","journal-title":"Br J Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002292.pub4","article-title":"Interventions for bullous pemphigoid","volume":"8","author":"Singh S","year":"2023","unstructured":"Singh S, Kirtschig G, Anchan VN, Chi CC, Taghipour K, Boyle RJ, Murrell DF. Interventions for bullous pemphigoid. Cochrane Database Syst Rev. 2023, 8:CD002292. 10.1002\/14651858.CD002292.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.3425","article-title":"Bullous pemphigoid severity and levels of antibodies to BP180 and BP230: a systematic review and meta-analysis","volume":"160","author":"Chou PY","year":"2024","unstructured":"Chou PY, Yu CL, Wen CN, Tu YK, Chi CC. Bullous pemphigoid severity and levels of antibodies to BP180 and BP230: a systematic review and meta-analysis. JAMA Dermatol. 2024, 160:1192-200. 10.1001\/jamadermatol.2024.3425","journal-title":"JAMA Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-025-00595-5","article-title":"Bullous pemphigoid","volume":"11","author":"Akbarialiabad H","year":"2025","unstructured":"Akbarialiabad H, Schmidt E, Patsatsi A, et al.. Bullous pemphigoid. Nat Rev Dis Primers. 2025, 11:12. 10.1038\/s41572-025-00595-5","journal-title":"Nat Rev Dis Primers"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.5049","article-title":"Assessment of the prevalence of mucosal involvement in bullous pemphigoid","volume":"155","author":"Kridin K","year":"2019","unstructured":"Kridin K, Bergman R. Assessment of the prevalence of mucosal involvement in bullous pemphigoid. JAMA Dermatol. 2019, 155:166-71. 10.1001\/jamadermatol.2018.5049","journal-title":"JAMA Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30560-3","article-title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial","volume":"389","author":"Williams HC","year":"2017","unstructured":"Williams HC, Wojnarowska F, Kirtschig G, et al.. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet. 2017, 389:1630-8. 10.1016\/S0140-6736(17)30560-3","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1155181","article-title":"Associations between bullous pemphigoid and hematological diseases: literature review on mechanistic connections and possible treatments","volume":"14","author":"Yang Y","year":"2023","unstructured":"Yang Y, Zhao W, Yang N, Cui S, Jin H, Li L. Associations between bullous pemphigoid and hematological diseases: literature review on mechanistic connections and possible treatments. Front Immunol. 2023, 14:1155181. 10.3389\/fimmu.2023.1155181","journal-title":"Front Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14738","article-title":"Comorbid diseases among bullous pemphigoid patients in Germany: new insights from a case-control study","volume":"20","author":"Martin E","year":"2022","unstructured":"Martin E, Mauer I, Malzahn U, Heuschmann PU, Goebeler M, Benoit S. Comorbid diseases among bullous pemphigoid patients in Germany: new insights from a case-control study. J Dtsch Dermatol Ges. 2022, 20:798-805. 10.1111\/ddg.14738","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref9","article-title":"Rook's Dermatology Handbook","author":"Griffiths CEM","year":"2021","unstructured":"Griffiths CEM, Bleiker TO, Creamer D, Ingram JR, Simpson RC. Rook's Dermatology Handbook. Wiley-Blackwell, 2021."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts","volume":"66","author":"Murrell DF","year":"2012","unstructured":"Murrell DF, Daniel BS, Joly P, et al.. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol. 2012, 66:479-85. 10.1016\/j.jaad.2011.06.032","journal-title":"J Am Acad Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2007.0090","article-title":"Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus","volume":"17","author":"Pf\u00fctze M","year":"2007","unstructured":"Pf\u00fctze M, Niedermeier A, Hertl M, Eming R. Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus. Eur J Dermatol. 2007, 17:4-11. 10.1684\/ejd.2007.0090","journal-title":"Eur J Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19611","article-title":"International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid","volume":"184","author":"Masmoudi W","year":"2021","unstructured":"Masmoudi W, Vaillant M, Vassileva S, et al.. International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid. Br J Dermatol. 2021, 184:1106-12. 10.1111\/bjd.19611","journal-title":"Br J Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2473","article-title":"The reliability, validity and responsiveness of two disease scores (BPDAI and ABSIS) for bullous pemphigoid: which one to use?","volume":"97","author":"Wijayanti A","year":"2017","unstructured":"Wijayanti A, Zhao CY, Boettiger D, Chiang YZ, Ishii N, Hashimoto T, Murrell DF. The reliability, validity and responsiveness of two disease scores (BPDAI and ABSIS) for bullous pemphigoid: which one to use?. Acta Derm Venereol. 2017, 97:24-31. 10.2340\/00015555-2473","journal-title":"Acta Derm Venereol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.928621","article-title":"Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review","volume":"13","author":"Cao P","year":"2022","unstructured":"Cao P, Xu W, Zhang L. Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review. Front Immunol. 2022, 13:928621. 10.3389\/fimmu.2022.928621","journal-title":"Front Immunol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.03.049","article-title":"Rituximab therapy in patients with bullous pemphigoid: a retrospective study of 20 patients","volume":"81","author":"Polansky M","year":"2019","unstructured":"Polansky M, Eisenstadt R, DeGrazia T, Zhao X, Liu Y, Feldman R. Rituximab therapy in patients with bullous pemphigoid: a retrospective study of 20 patients. J Am Acad Dermatol. 2019, 81:179-86. 10.1016\/j.jaad.2019.03.049","journal-title":"J Am Acad Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00688-x","article-title":"Clinical effectiveness and safety of initial combination therapy with corticosteroids and rituximab in bullous pemphigoid: a retrospective cohort study","volume":"23","author":"Tsai YJ","year":"2022","unstructured":"Tsai YJ, Cho YT, Chu CY. Clinical effectiveness and safety of initial combination therapy with corticosteroids and rituximab in bullous pemphigoid: a retrospective cohort study. Am J Clin Dermatol. 2022, 23:571-85. 10.1007\/s40257-022-00688-x","journal-title":"Am J Clin Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17616","article-title":"Clinical characteristics of bullous pemphigoid patients of different ages and the possible mechanism","volume":"52","author":"Chen X","year":"2025","unstructured":"Chen X, Zhang B, Mao X, et al.. Clinical characteristics of bullous pemphigoid patients of different ages and the possible mechanism. J Dermatol. 2025, 52:672-81. 10.1111\/1346-8138.17616","journal-title":"J Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02219","article-title":"A retrospective study of patient-reported data of bullous pemphigoid and mucous membrane pemphigoid from a US-based registry","volume":"10","author":"Lee J","year":"2019","unstructured":"Lee J, Seiffert-Sinha K, Attwood K, Sinha AA. A retrospective study of patient-reported data of bullous pemphigoid and mucous membrane pemphigoid from a US-based registry. Front Immunol. 2019, 10:2219. 10.3389\/fimmu.2019.02219","journal-title":"Front Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01607","article-title":"Assessment of the characteristics and associated factors of infectious complications in bullous pemphigoid","volume":"11","author":"Chen J","year":"2020","unstructured":"Chen J, Mao X, Zhao W, et al.. Assessment of the characteristics and associated factors of infectious complications in bullous pemphigoid. Front Immunol. 2020, 11:1607. 10.3389\/fimmu.2020.01607","journal-title":"Front Immunol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt E","year":"2013","unstructured":"Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013, 381:320-32. 10.1016\/S0140-6736(12)61140-4","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/495338-suprabasal-blistering-as-a-diagnostic-pitfall-in-bullous-pemphigoid-histopathologic-immunofluorescence-discordance-complicated-by-sepsis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:09:06Z","timestamp":1788350946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/495338-suprabasal-blistering-as-a-diagnostic-pitfall-in-bullous-pemphigoid-histopathologic-immunofluorescence-discordance-complicated-by-sepsis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.115641","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,2]]}}}